What is the ROE (Return on Equity) of Merus this year?
The ROE of Merus this year is -0.43 undefined.
Merus ROE 2024
Merus ROE
-0.43
Ticker
MRUS
ISIN
NL0011606264
WKN
A2AKFX
In 2024, Merus's return on equity (ROE) was -0.43, a -18.1% increase from the -0.53 ROE in the previous year.
Merus Aktienanalyse
What does Merus do?
Merus NV is a Dutch biotechnology company specialized in the development of innovative therapies for cancer and other serious diseases. The company was founded in 2003 by Ton Logtenberg and Piet Gros and is headquartered in Utrecht. Merus' business model is based on the development of bispecific antibodies, which can bind to two different target structures simultaneously. These antibodies can specifically attack and destroy tumor cells by minimizing their binding to healthy cells, providing Merus with a high potential for cancer therapy and other diseases. The company is divided into two main divisions: Merus BV and Merus US Inc. Merus BV specializes in the development of bispecific antibodies and operates its own manufacturing facility in Utrecht, while Merus US Inc. focuses on the clinical development of cancer immunotherapies. Merus offers a variety of products, including Bispecific Antibodies for Multiple Targets (BAMTs), Multi-specific Antibodies (MSAs), TrioBody platform, and Smart-chemotherapy platform. The BAMT program aims to develop bispecific antibodies that can bind to multiple target structures simultaneously, enhancing their effectiveness against tumor cells. The company's MSA products aim to introduce a bispecific antibody system with specialized drainage function to enhance the efficiency of cancer treatments. Merus' TrioBody platform represents a form of bispecific antibodies specifically tailored to cells in tumors, providing a higher efficacy in destroying tumor cells compared to conventional antibodies. Merus' Smart-Chemotherapy platform aims to increase the efficiency of chemotherapy drugs by delivering the medication specifically to tumor cells, maximizing its effect on tumor cells while minimizing its effect on normal cells. The company has entered into various partnerships and collaborations with other companies to advance its research and development in the field of cancer immunotherapy. In 2018, Merus signed an agreement with Incyte, granting Incyte the right to use Merus' bispecific antibody platform for cancer treatment. Additionally, Merus has formed strategic alliances with other biotechnology companies such as Jazz Pharmaceuticals and Loxo Oncology to further develop in various areas of cancer immunotherapy. Merus is committed to continue investing in research and development of its antibody technology to increase the effectiveness of cancer treatments and provide patients worldwide with new therapies to combat cancer. Merus ist eines der beliebtesten Unternehmen auf Eulerpool.com.ROE Details
Decoding Merus's Return on Equity (ROE)
Merus's Return on Equity (ROE) is a fundamental metric evaluating the company's profitability relative to its equity. Calculated by dividing net income by shareholder's equity, ROE illustrates how effectively the company is generating profits from shareholders’ investments. A higher ROE represents enhanced efficiency and profitability.
Year-to-Year Comparison
Analyzing Merus's ROE on a yearly basis aids in tracking its profitability trends and financial performance. An increasing ROE suggests enhanced profitability and value generation for shareholders, whereas a declining ROE may indicate issues in profit generation or equity management.
Impact on Investments
Merus's ROE is instrumental for investors assessing the company's profitability, efficiency, and investment attractiveness. A robust ROE indicates the firm’s adeptness at converting equity investments into profits, thereby enhancing its appeal to potential and current investors.
Interpreting ROE Fluctuations
Changes in Merus’s ROE can emanate from variations in net income, equity capital, or both. These fluctuations are scrutinized to evaluate management’s effectiveness, financial strategies, and the inherent risks and opportunities, aiding investors in making informed decisions.
Frequently Asked Questions about Merus stock
How has the Return on Equity (ROE) of Merus developed compared to the previous year?
The ROE of Merus has increased by -18.1% decreased compared to the previous year.
What impact does a high ROE (Return on Equity) have on investors of Merus?
A high ROE indicates that Merus generates good returns on capital and is successful in monetizing its investments. This is a positive indicator for investors.
What impact does a low ROE (Return on Equity) have on investors of Merus?
A low ROE can indicate that Merus is having difficulties monetizing its investments successfully and can be a negative signal for investors.
How does a change in the ROE (Return on Equity) of Merus affect the company?
A change in ROE (Return on Equity) of Merus can be an indicator of the financial performance of the company and demonstrate how successful the company is compared to other companies in the same industry.
How to calculate the ROE (Return on Equity) of Merus?
The ROE (Return on Equity) is calculated by dividing the company's profit by the total equity. The formula is: ROE = Profit / Total equity.
Which factors influence the ROE (Return on Equity) of Merus?
Some factors that can influence Merus's Return on Equity (ROE) include the efficiency in using equity, the profitability of the company, and the financing structure.
What strategic measures can take to improve the ROE (Return on Equity)?
To improve the Return on Equity (ROE), can take measures such as cost savings, increasing revenue, improving efficiency in the use of equity, and making changes in the financing structure. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to improve ROE.
How much dividend does Merus pay?
Over the past 12 months, Merus paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Merus is expected to pay a dividend of 0 USD.
What is the dividend yield of Merus?
The current dividend yield of Merus is .
When does Merus pay dividends?
Merus pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Merus?
Merus paid dividends every year for the past 0 years.
What is the dividend of Merus?
For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.
In which sector is Merus located?
Merus is assigned to the 'Health' sector.
Wann musste ich die Aktien von Merus kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Merus from 9/13/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 9/13/2024.
When did Merus pay the last dividend?
The last dividend was paid out on 9/13/2024.
What was the dividend of Merus in the year 2023?
In the year 2023, Merus distributed 0 USD as dividends.
In which currency does Merus pay out the dividend?
The dividends of Merus are distributed in USD.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Merus
Our stock analysis for Merus Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Merus Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
